Evercore ISI raised the firm’s price target on Privia Health (PRVA) to $30 from $28 and keeps an Outperform rating on the shares. The company’s execution track record merits a premium valuation, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Privia Health price target raised to $31 from $30 at Citizens JMP
- Privia Health Reports Strong Q3 2025 Results
- Privia Health Group: Strong Financial Performance and Strategic Growth Justify Buy Rating
- Privia Health files automatic mixed securities shelf
- Privia Health Group: Strong Financial Performance and Strategic Positioning Drive Buy Rating